source
- FDA suspends National Priority Voucher pilot and pauses release of complete response lettersThe Food and Drug Administration has quietly ended the National Priority Voucher pilot, a program that was designed to speed the review of certain drug candidates. In addition, the agency appears…
- Vor Bio pays RemeGen $10 million for rights to long-acting autoimmune drug candidate RC298Vor Bio announced a licensing agreement with RemeGen, paying $10 million upfront in cash and issuing warrants valued at about $46 million for rights to RC298 outside Greater China. RC298 is a long…